Health
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
FOSTER CITY, Calif., January 12, 2026--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":280,"url":"https://media.zenfs.com/en/business-wire.com/8330fea52cabbaa8f5fa82386fa0c339"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ne5E9b1W8cqbPJGA_AQ6pA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8330fea52cabbaa8f5fa82386fa0c339","width":480,"height":280}},"lazy":false},{"type":"text","content":"- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"- 2026 expected global net product sales of $630 million to $650 million","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"- Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected Q2 2026","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"- LIVMARLI® EXPAND study in additional cholestatic pruritus settings timing accelerated; topline data now expected Q4 2026","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"- Proposed acquisition of Bluejay Therapeutics to add AZURE Phase 3 studies of brelovitug in chronic hepatitis delta virus (HDV); topline data expected H2 2026","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"FOSTER CITY, Calif., January 12, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and full-year 2026 outlook.","length":293,"tagName":"p"},{"type":"text","content":""2025 was an excellent year for Mirum, reflecting the strength and scalability of our purpose-built rare disease operating model," said Chris Peetz, Chief Executive Officer of Mirum. "We delivered strong global commercial growth, advanced multiple late-stage clinical programs and are expanding our pipeline with the proposed acquisition of Bluejay Therapeutics and brelovitug for HDV. With a strong financial foundation, deep commitment to patients and multiple upcoming clinical catalysts, we enter 2026 well positioned to drive continued execution and value creation."","length":591,"tagName...